BioSpace News Archive

Pharma Industry in Crisis: How to Preserve Quality While Balancing Budget and Time in Today’s Financial Climate

With venture funding tightening in the post-COVID landscape, efficiency has become more critical than ever. In this interactive webinar industry experts will explore actionable strategies for maintaining quality under financial pressure.

May 30, 2025

Beautiful downtown Chicago morning along the river as people jog on the path below and train crosses a bridge as the sun casts yellow light into the scene from behind the high-rise buildings beyond.

#ASCO25 Tracker: BioNTech, OSE Tout Positive Data in Difficult Cancers

BioSpace is on site to keep you updated on all of the biggest data and news from the conference.

May 30, 2025

·

BioSpace Editorial Staff

Contemporary art collage. Businessman putting voting paper into ballot box sticking out from retro computer motinor. Choosing right candidate to run he company. Online voting, election concept

Diversity, equity & inclusion

Merck CEO Calls Diversity ‘Core’ to Operations as Anti-DEI Measure Is Defeated

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI goals in executive pay incentives.

May 30, 2025

·

3 min read

·

Annalee Armstrong

Lung Cancer

Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient populations.

May 30, 2025

·

3 min read

·

Nick Paul Taylor

Businessman makes employee cuts as part of layoff

Layoffs

After Safety Stumbles, Keros Axes Pulmonary Hypertension Drug, 45% of Staff

Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

May 30, 2025

·

2 min read

·

Tristan Manalac

Vertical collage image of black white effect arm hold tied arrow shoot down darts board target isolated on painted background.

Immunology and inflammation

Sanofi, Regeneron Shares Tumble as Dupixent Follow-Up Fails Phase III COPD Test

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their blockbuster Dupixent in the I&I space, was “contrary to our expectations—we were wrong.”

May 30, 2025

·

3 min read

·

Annalee Armstrong

Government

Fake Citations Plague RFK Jr.’s MAHA Report

According to the nonprofit news outlet NOTUS, at least seven studies cited in the Make America Healthy Again report released last week are nonexistent. The White House shrugged off questions about the errors.

May 30, 2025

·

2 min read

·

Tristan Manalac

Collaboration

Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric cancer and pancreatic cancer.

May 30, 2025

·

2 min read

·

Tristan Manalac

Illustration showing line of people leaving, standing on top of hand pointing their way out

Layoffs

Stealth Cuts 30% of Workforce Following FDA Rejection, Still Eyes Barth Approval

Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified a potential accelerated approval pathway. The company has pared down its staff to conserve resources to fund a potential resubmission.

May 30, 2025

·

2 min read

·

Angela Gabriel

Press Releases

Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 30, 2025

·

4 min read